V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 140026071 | 140017744 | 1.69 | 68.1 | null | 2018-08-27 | 2018-09-03 | CISPLATIN + FLUOROURACIL | y | N | CISPLATIN + FLUOROURACIL | 101067468 |
| 70071317 | 70132160 | 0 | 92.5 | Curative (C) | null | 2016-06-05 | AML 19 TRIAL | y | N | METHOTREXATE INTRATHECAL | 101696745 |
| 70085821 | 70103569 | 1.87 | 66.8 | Curative (C) | 2019-06-16 | 2019-06-20 | ALL UKALL2011 Aug BFM Cons C PegAsp | y | N | UKALL2014 | 101119904 |
| 70084675 | 70103315 | 1.63 | 67.8 | Adjuvant (A) | 2019-03-20 | 2019-03-25 | Trial Unspecified | y | Y | TRIAL | 100970215 |
| 70084402 | 70103260 | 1.47 | 86.8 | null | 2021-09-07 | 2021-09-07 | Bortezomib + MELPHALAN | y | N | BORTEZOMIB + MELPHALAN | 100877070 |
| 70083414 | 70103071 | 1.44 | 66.4 | null | 2016-09-19 | 2016-09-24 | ALL UKALL2011 Aug BFM Cons C PegAsp | y | N | TRIAL | 100210954 |
| 70082641 | 70102897 | 1.65 | 36.6 | null | 2018-08-11 | 2018-11-27 | Bortezomib + MELPHALAN | y | N | BORTEZOMIB + MELPHALAN | 101460391 |
| 70070929 | 70097933 | 0 | 73.8 | Curative (C) | 2016-06-23 | 2016-06-23 | Methotrexate intrathecal | y | N | POMALIDOMIDE | 100377738 |
| 40169108 | 40125171 | 0 | 0 | Curative (C) | 2015-06-10 | 2015-06-29 | CAP | y | null | PERTUZUMAB | 100210903 |
| 70069195 | 70097159 | 1.71 | 14 | 03 | 2016-11-13 | 2016-12-23 | Azacitidine | y | null | AZACITIDINE | 100053959 |
| 70091452 | 70058965 | 1.58 | 51 | Curative (C) | 2019-07-29 | 2019-08-06 | AML 18 TRIAL | y | N | AML18 TRIAL | 101181485 |
| 70086944 | 70055038 | null | null | null | 2016-02-21 | 2016-03-20 | CTD Attenuated (Thalidomide 50mg) | y | null | CTD | 100486105 |
| 70086945 | 70182337 | 1.65 | 37.5 | null | 2019-12-30 | 2020-02-04 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | y | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101468891 |
| 70087931 | 70172646 | 1.58 | 102 | Curative (C) | 2020-04-11 | 2020-05-18 | ALL UKALL2011 Aug BFM Cons C PegAsp | y | N | TRIAL | 100052464 |
| 70083694 | 70172058 | 1.56 | 75 | null | 2018-01-09 | 2018-01-09 | Cyclophos + Dex + Lenalidomide | y | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100367128 |
| 70086981 | 70157852 | 1.7 | 73 | Curative (C) | 2020-10-31 | 2020-11-08 | Trial Unspecified | y | null | TRIAL | 101783260 |
| 70086148 | 70157716 | 1.74 | 48.6 | 03 | 2017-10-03 | 2017-10-05 | ALL UKALL2011 Aug BFM Cons C PegAsp | y | N | TRIAL | 101591484 |
| 70073297 | 70155392 | 1.86 | 85.2 | Disease modification (D) | 2020-05-09 | 2020-06-04 | AML 19 TRIAL | y | N | METHOTREXATE INTRATHECAL | 101823376 |
| 70072537 | 70155274 | 1.62 | 81 | Curative (C) | 2022-03-20 | 2022-03-26 | AML 19 TRIAL | y | N | POMALIDOMIDE | 101140986 |
| 70072435 | 70155252 | 1.84 | 136.4 | Curative (C) | 2020-03-23 | 2020-04-28 | Methotrexate intrathecal | y | N | AML19 TRIAL | 100695319 |
| 70071641 | 70155092 | 0 | 68 | Curative (C) | 2020-01-19 | 2020-01-26 | AML 19 TRIAL | y | null | AML19 TRIAL | 101802303 |
| 70083681 | 70135575 | 1.72 | 81 | Palliative (P) | null | 2018-09-05 | DA 3+8 | y | N | CYTARABINE + DAUNORUBICIN | 100911265 |
| 70080120 | 70134917 | 1.46 | 81.7 | Disease modification (D) | 2020-01-23 | 2020-01-23 | ALL UKALL2011 Ind A Sht Dex (PAsp) | y | null | TRIPLE INTRATHECAL | 100401959 |
| 70069421 | 70131518 | 1.64 | 69.8 | Palliative (P) | 2021-04-15 | 2021-04-15 | Azacitidine | y | N | AZACITIDINE | 100455821 |
| 70091628 | 70059120 | 1.74 | 53.8 | Curative (C) | 2017-05-24 | 2017-05-24 | AML 18 TRIAL | y | N | AML18 TRIAL | 100921802 |
| 60104247 | 60045072 | 1.78 | 137 | null | 2016-04-29 | 2016-05-06 | Erlotinib | n | N | CRIZOTINIB | 100088160 |
| 60008807 | 60043937 | 1.8 | 68.6 | Disease modification (D) | 2018-09-12 | 2018-09-14 | CETUXIMAB + RT | n | N | CARBOPLATIN + FLUOROURACIL | 101525637 |
| 40164916 | 40281007 | 1.64 | 60.2 | Palliative (P) | 2017-11-14 | 2017-12-05 | FEC 100 | n | N | FEC | 100426036 |
| 70077379 | 70050000 | 1.75 | 80.8 | Palliative (P) | 2020-09-24 | 2020-10-13 | CHLORAMBUCIL + OBINUTUZUMAB | n | N | CHLORAMBUCIL + OBINUTUZUMAB | 100520204 |
| 150011256 | 150006165 | 1.81 | 75.4 | Palliative (P) | 2019-07-30 | 2019-08-04 | Temozolomide + RT | n | Y | TEMOZOLOMIDE | 100176412 |
| 160012934 | 160006259 | 1.74 | 100 | Neo-adjuvant (N) | 2017-11-27 | 2017-12-13 | BEVACIZUMAB + CARBO + PACLITAXEL | n | N | DOXORUBICIN + OLARATUMAB | 101586702 |
| 160013044 | 160006322 | 1.78 | 77.5 | Palliative (P) | null | 2017-12-21 | Doxorubicin 75mg/m2 | n | N | CISPLATIN + DOXORUBICIN | 100513918 |
| 160013734 | 160006691 | 1.51 | 17.4 | Palliative (P) | null | 2017-03-28 | CISPLATIN + ETOPOSIDE | n | N | TRIAL UNSPECIFIED | 100790731 |
| 160013971 | 160006837 | 1.81 | 96.7 | Palliative (P) | null | 2019-10-21 | Liposomal Doxorubicin (Caelyx) | n | N | LIPOSOMAL DOXORUBICIN | 100903584 |
| 150007532 | 150004139 | 1.69 | 52.4 | Palliative (P) | null | 2019-08-31 | Temozolomide + RT | n | N | TEMOZOLOMIDE | 100996523 |
| 160015394 | 160007624 | 1.76 | 96.6 | Palliative (P) | 2018-08-22 | 2018-08-22 | Paclitaxel 80mg/m2 day 1 8 15 | n | N | TRIAL | 101565022 |
| 30156428 | 30119130 | 1.73 | 65 | null | 2019-06-06 | 2019-07-15 | Carboplatin + Vinorelbine IV &PO D8 | n | null | ETOPOSIDE | 101259209 |
| 20035560 | 20169454 | 1.73 | 56.2 | null | 2019-04-25 | 2019-11-06 | null | Y | null | NOT MATCHED | 100425915 |
| 20205236 | 20153740 | 1.81 | 85 | null | 2017-07-09 | 2019-08-21 | Cetuximab 14 day | Y | null | CETUXIMAB | 101399570 |
| 20216443 | 20168631 | 1.75 | 73.3 | Palliative (P) | null | 2020-02-06 | Cetuximab + FOLFIRI cycle 2 onwards | Y | N | CETUXIMAB + IRINOTECAN + MDG | 101628047 |
| 20211128 | 20154332 | 1.73 | 90.3 | Palliative (P) | 2020-08-26 | 2020-09-01 | GEMCITABINE + NAB PACLITAXEL | Y | N | GEMCITABINE + NAB-PACLITAXEL | 100056162 |
| 20215156 | 20155485 | 1.72 | null | Palliative (P) | 2020-10-21 | 2020-11-08 | EOX | Y | N | CETUXIMAB + IRINOTECAN + MDG | 101497143 |
| 20215716 | 20155665 | 1.84 | 47.3 | Palliative (P) | 2018-04-25 | 2018-05-01 | Oxaliplatin + Raltitrexed | Y | N | OXALIPLATIN + RALTITREXED | 101488633 |
| 20216015 | 20155749 | 1.54 | 75 | null | 2016-02-28 | 2016-04-09 | Trial Unspecified | Y | null | TRIAL | 100791060 |
| 20216314 | 20155852 | 1.75 | 90.5 | Adjuvant (A) | null | 2017-10-24 | Sorafenib | Y | N | SORAFENIB | 100441786 |
| 20216442 | 20155893 | 1.69 | 88 | Curative (C) | 2019-08-19 | 2019-09-21 | EOX | Y | Y | OXALIPLATIN + RALTITREXED | 101830442 |
| 20039998 | 20158317 | 1.77 | 68.5 | Curative (C) | 2017-06-10 | 2019-04-01 | PACLITAXEL + TRASTUZUMAB | Y | null | CAPE + OXALIPLATIN + TRASTUZUMAB | 101839329 |
| 20187764 | 20165858 | 1.84 | 81 | null | 2017-03-27 | 2017-03-27 | Folfirinox | Y | null | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 100400499 |
| 20217626 | 20168755 | 1.75 | 68.1 | Palliative (P) | 2019-07-30 | 2019-08-13 | EOX | Y | N | CETUXIMAB + IRINOTECAN + MDG | 100349850 |
| 20215209 | 20155501 | 1.75 | 75.9 | Neo-adjuvant (N) | 2019-02-13 | 2019-06-16 | Sorafenib | Y | Y | SORAFENIB | 100151323 |